恒瑞医药发布2025年年度权益分派实施公告，股东分红细节披露
要点概览
- 每股现金红利： 0.2元（含税），以6,372,105,824股为基数发放。
- 总派发金额： 12.74亿元人民币。
- 股权登记日： 2026年5月26日。
- 除权（息）日及现金红利发放日： 均为2026年5月27日。
- 差异化分红： 本次分红为差异化分红，公司回购股份不参与分配。
- 无送转方案： 仅现金分红，无送股、转增。
- 税收政策： 个人股东、QFII、沪港通投资者等不同持有人适用不同税率与征收方式，持股期限影响实际税负。
分红详情与时间安排
恒瑞医药（600276）公布了2025年度权益分派实施方案，明确将以截至2026年5月26日收市后登记在册的A股股东为对象，每持有1股派发0.2元现金红利（含税）。本次分红总基数为6,372,105,824股（已扣除回购专用账户股份），总现金分红金额约为12.74亿元人民币。
本次分红不涉及送股或转增，仅进行现金红利分配，体现公司稳定的现金流和回馈投资者的意愿。
差异化分红与除权价格计算
本次权益分派为差异化分红，回购股份（6,896,450股）不参与分红分配。除权（息）参考价格的计算为：
除权(息)参考价格 = 前收盘价格 - 0.20元/股，其中流通股份未发生变化。投资者需留意除权日股价可能因分红而下调。
现金红利发放方式
- 除指定对象自行发放外，其他无限售条件流通股东的红利由中国结算上海分公司通过资金清算系统派发。已办理指定交易的投资者可在证券营业部领取红利，未办理的则由结算公司暂时保管。
- 回购专用账户股份不参与利润分配。
- 主要股东如江苏恒瑞医药集团有限公司、上海启创达远企业管理有限公司等将由公司自行发放红利。
税收政策与实际到手分红说明
- 个人股东及证券投资基金：
- 持股超1年：红利所得暂免征收个人所得税，每股到手0.2元。
- 持股1年及以内：暂不扣税，待转让时再按持有期限计算税额，1个月内实际税负20%、1个月至1年（含）为10%。
- QFII（合格境外机构投资者）：
- 公司按10%税率代扣代缴，税后每股派发0.18元。如享受税收协定需自行向税务机关申请。
- 沪港通投资者：
- 统一按10%税率代扣代缴，税后每股派发0.18元。
- 其他机构投资者：
- 红利税由投资者自行申报缴纳，税前每股派发0.2元。
对股价及投资者的潜在影响
- 本次现金分红力度较大，显示公司盈利能力和现金流稳定，或提振投资者信心。
- 除权日后，股价将因分红进行价格调整，短期内或对股价形成技术性下调，投资者需关注市场波动。
- 税收政策复杂，不同投资者实际到手分红金额差异较大，建议投资者根据持股期限和身份合理安排税务规划。
- 回购股份不参与分红，显示公司持续通过回购与分红组合回馈股东。
投资者咨询渠道
如有疑问，可联系恒瑞医药资本市场和证券事务部，联系电话：021-61053323。
免责声明
本文内容仅供投资者参考，不构成任何投资建议。投资有风险，入市需谨慎。请投资者关注自身税收负担及市场波动风险，详细信息请以公司公告为准。
English Translation
Hengrui Medicine Releases 2025 Annual Dividend Distribution Implementation Details
Key Highlights
- Cash Dividend per Share: RMB 0.2 (pre-tax), based on 6,372,105,824 shares.
- Total Distribution: Approx. RMB 1.274 billion.
- Shareholder Record Date: May 26, 2026.
- Ex-dividend and Dividend Payment Date: Both on May 27, 2026.
- Differentiated Dividend: Repurchased shares do not participate in this distribution.
- No Bonus Shares or Capitalization: Only cash dividends, no bonus or capitalization shares.
- Tax Policy: Different tax rates and collection methods apply for individuals, QFIIs, and Hong Kong investors; actual after-tax dividend depends on holding period and investor type.
Dividend Details and Timeline
Hengrui Medicine (600276) has announced the implementation of its 2025 annual rights distribution plan. As of the close of trading on May 26, 2026, all A-share holders registered will receive RMB 0.2 cash dividend per share (pre-tax), based on a total of 6,372,105,824 shares (excluding repurchased shares). The total cash dividend amounts to about RMB 1.274 billion.
This dividend scheme does not include any bonus shares or capitalization; it is purely a cash dividend, demonstrating the company’s strong cash flow and commitment to shareholder returns.
Differentiated Dividend and Ex-dividend Price Calculation
This distribution follows a differentiated dividend model, with repurchased shares (6,896,450 shares) excluded from participation. The ex-dividend reference price is calculated as:
Ex-dividend reference price = Previous closing price - RMB 0.20/share, with no change in free float shares. Investors should note that the stock price will be technically adjusted downward on the ex-dividend date.
Dividend Payment Method
- Except for specified recipients, dividends for all other unrestricted tradable shares will be paid via China Securities Depository and Clearing Shanghai branch’s fund clearing system. Investors with designated trading can receive the dividend at their securities branch; those without will have funds temporarily held by the clearing company.
- Shares in the repurchase account are excluded from profit distribution.
- Main shareholders such as Jiangsu Hengrui Medicine Group, Shanghai Qichuang Dayuan, etc., will have dividends paid directly by the company.
Tax Policy and Net Dividend Details
- Individual shareholders and public funds:
- Holding over 1 year: Dividend temporarily exempt from personal income tax, net RMB 0.2/share.
- Holding 1 year or less: No tax withheld initially; tax calculated upon sale of shares. Holding ≤1 month: 20% tax; holding >1 month to 1 year (inclusive): 10% tax.
- QFIIs (Qualified Foreign Institutional Investors):
- Company withholds 10% corporate tax, net dividend RMB 0.18/share. For tax treaty benefits, application must be made to the tax authorities.
- Hong Kong Stock Connect Investors:
- 10% withholding tax applied, net RMB 0.18/share.
- Other institutional investors:
- Responsible for their own tax filings, gross dividend RMB 0.2/share.
Potential Impact on Stock Price and Investors
- This sizeable cash dividend signals strong profitability and cash flow, likely boosting investor confidence.
- The stock price will adjust downward by RMB 0.20/share on the ex-dividend date, possibly triggering short-term volatility.
- The complex tax policy means actual net dividend varies significantly among different investors—tax planning is advised.
- Exclusion of repurchased shares in the dividend reflects the company’s continued use of both buybacks and dividends to reward shareholders.
Investor Inquiry Channel
For questions, investors may contact Hengrui Medicine’s Capital Markets and Securities Affairs Department at 021-61053323.
Disclaimer
The content herein is for reference only and does not constitute investment advice. Investments are subject to risk; please invest prudently. For details, refer to the official company announcement and consider your own tax and market risk positions.
